Protracted clinical and inflammatory response to rhinovirus challenge in human asthmatics
Protracted clinical and inflammatory response to rhinovirus challenge in human asthmatics
批准号:
10540527
负责人:
LARRY C BORISH
金额:
$32.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-01 至 2023-08-31
关键词:
AllergensAllergicAsthmaBiopsyBronchial HyperreactivityCell CompartmentationCellsClinicalConfocal MicroscopyDevelopmentEpigenetic ProcessEpithelialEpithelial CellsFlow CytometryFutureGenerationsGoblet CellsHumanImmuneImmunohistochemistryInfectionInflammationInflammatoryInflammatory ResponseInnate Immune SystemInterleukin-13Interleukin-5InterleukinsLocationLymphocyteLymphoidMediatingMemoryMetaplasiaModelingOutcomePathway interactionsPhenotypePhysiologicalPopulationPredispositionProcessProductionRecurrenceRespiratory Signs and SymptomsRespiratory Tract InfectionsRhinovirusRhinovirus infectionRiskSeveritiesSymptomsTSLP geneTissuesadaptive immune responseairborne allergenairway epitheliumairway inflammationairway remodelingassociated symptomasthma exacerbationasthmaticcell typechemokinecohortcytokineeosinophileosinophilic inflammationgene discoveryinflammatory milieumast cellnovelpulmonary functionreceptorrecruitrespiratory virusresponsesingle-cell RNA sequencingtranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Rhinovirus (RV) infections are the most common cause of asthma exacerbations and our previous studies with
experimental RV-A16 inoculations demonstrate the ability of this model to recapitulate the physiological and
immune consequences of natural infections. What has never previously been appreciated is that asthmatics
consistently also demonstrate recurrence of upper and lower airway symptoms peaking 2-3 weeks post-
inoculation. RV inoculation in asthmatics is associated with rapid development of an eosinophilic response in
the airway that peaks at 2-4 days post-infection (dpi). This increase in eosinophilic inflammation evolves too
rapidly to be explained by an adaptive immune response, however, the ability of the innate immune system to
exacerbate an established type 2 inflammatory state is recognized. This reflects generation by a dysmatured
epithelial cells (EpC) compartment of a type 2 inflammation-promoting milieu including release of the cytokines
interleukin (IL)-25, IL-33, and TSLP. IL-25 has recently been recognized to be exclusively produced by a
differentiated EpC termed the solitary chemosensory cell (SCC). All 3 cytokines activate immune cells of the
airway, including innate lymphoid 2 cells (ILC2s). But other cells including mast cells express their receptors
and will respond with secretion of IL-5 and IL-13. Along with enhanced expression of other epithelial-derived
eosinophil-activating cytokines, this explains the exacerbation of eosinophilic inflammation and symptoms
observed within 2-3 days of the inoculation. In the proposed studies, we are particularly eager to explore
mechanisms responsible for the protracted worsening of airway symptoms and inflammation. The increase in
IL-13 production will promote the further differentiation of goblet cells and SCCs and we predict that these will
comprise an increasingly high proportion of airway EpCs over 2-3 weeks. SCC-derived IL-25 (and other
cytokines) will then promote the expansion of mast cells and ILC2s. However, this late recurrence of asthma
symptoms is occurring in the presence of ongoing aeroallergen exposure. Our studies have demonstrated the
ability of RV to enhance adaptive immune responses to bystander aeroallergens. The interaction of allergens
with expanded populations of mast cells and allergen-specific CD4+ tissue resident memory (TRM) lymphocytes
will establish a milieu that we propose underlies the protracted worsening of inflammation and symptoms. In
summary, we hypothesize that RV infection results in the rapid induction of an inflammatory response by a
dysmatured epithelial compartment, which leads to the exacerbation of a type 2 inflammatory state that is
responsible for the rapid development RV-induced asthma exacerbations. More importantly, we propose that
this RV infection will lead to the delayed expansion of SCCs, ILC2s, CD4+ TRM lymphocytes, and mast cells,
that leads to the recurrent/protracted worsening of respiratory symptoms and enhances susceptibility to further
exacerbations. This feedforward loop thereby forms the basis for a severe asthma phenotype characterized by
frequent exacerbations and, in some situations, to the irreversible loss of lung function.
1
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
The Impact of CFTR Modulator Triple Therapy on Type 2 Inflammatory Response in Patients with Cystic Fibrosis.
CFTR 调节剂三联疗法对囊性纤维化患者 2 型炎症反应的影响。
DOI:
10.21203/rs.3.rs-2846739/v1
发表时间:
2023
期刊:
Research square
影响因子:
--
作者:
[Mehta,Ajay, Lee,Irene, Li,Galvin, Jones,Marieke, Hanson,Lydia, Lonabaugh,Kevin, List,Rhonda, Borish,Larry, Albon,Dana]
通讯作者:
Albon,Dana
DOI:
10.1016/j.anai.2022.04.033
发表时间:
2022-07
期刊:
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
影响因子:
--
作者:
[L. Borish;W. Eschenbacher]
通讯作者:
L. Borish;W. Eschenbacher
Rethinking the central role of mast cells in virally mediated asthma exacerbations.
重新考虑肥大细胞在病毒介导的哮喘恶化中的核心作用。
DOI:
10.1016/j.anai.2022.03.029
发表时间:
2022-12
期刊:
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
影响因子:
5.9
作者:
[Borish, Larry]
通讯作者:
Borish, Larry
Insights into mechanisms of immunotherapy circa 1943: "What has been will be again".
1943 年左右对免疫治疗机制的见解:“已有之事,必将再次发生”。
DOI:
10.1016/j.anai.2023.01.035
发表时间:
2023
期刊:
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
影响因子:
--
作者:
[Borish,Larry]
通讯作者:
Borish,Larry
DOI:
10.1016/j.jaci.2020.05.039
发表时间:
2021-03
期刊:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
影响因子:
14.2
作者:
[Steinke, John W., Lawrence, Monica G., Teague, W. Gerald, Braciale, Thomas J., Patrie, James T., Borish, Larry]
通讯作者:
Borish, Larry
共 8 条
Clinical response to rhinovirus challenge in human asthmatics
-
批准号:9893778
-
项目类别:
-
资助金额:$69.98万
-
财政年份:2016
-
负责人:LARRY C BORISH
-
依托单位:
Clinical response to rhinovirus challenge in human asthmatics
-
批准号:9081696
-
项目类别:
-
资助金额:$69.98万
-
财政年份:2016
-
负责人:LARRY C BORISH
-
依托单位:
Clinical immune response to rhinovirus challenge in human asthmatics
-
批准号:9075457
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2015
-
负责人:LARRY C BORISH
-
依托单位:
CD4+ and CD8+ T cell dependent immune mechanisms of rhinovirus-mediated asthma ex
-
批准号:8077929
-
项目类别:
-
资助金额:$11.43万
-
财政年份:2010
-
负责人:LARRY C BORISH
-
依托单位:
CD4+ and CD8+ T cell dependent immune mechanisms of rhinovirus-mediated asthma ex
-
批准号:7975934
-
项目类别:
-
资助金额:$30.8万
-
财政年份:2010
-
负责人:LARRY C BORISH
-
依托单位:
Cysteinyl leukotrienes in chronic sinusitis and asthma
-
批准号:7167443
-
项目类别:
-
资助金额:$36.78万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Interplay between LTE4/LTE4 receptors and IFN-y with mast cells and eosinophils i
-
批准号:8450125
-
项目类别:
-
资助金额:$36.19万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Cysteinyl leukotrienes in chronic sinusitis and asthma
-
批准号:7561648
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Interplay between LTE4/LTE4 receptors and IFN-y with mast cells and eosinophils i
-
批准号:8259134
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Cysteinyl leukotrienes in chronic sinusitis and asthma
-
批准号:7761238
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Impact of chronic hyperplastic eoslnophilic sinusitis on asthma
-
批准号:7151382
-
项目类别:
-
资助金额:$24.08万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Interplay between LTE4/LTE4 receptors and IFN-y with mast cells and eosinophils i
-
批准号:8186070
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Cysteinyl leukotrienes in chronic sinusitis and asthma
-
批准号:7103793
-
项目类别:
-
资助金额:$37.98万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Interplay between LTE4/LTE4 receptors and IFN-y with mast cells and eosinophils i
-
批准号:8650250
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
Cysteinyl leukotrienes in chronic sinusitis and asthma
-
批准号:7340394
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2006
-
负责人:LARRY C BORISH
-
依托单位:
CT SCAN AND RHINOSCOPY TO MONITOR CHRONIC HYPERPLASTIC SINUSITIS
-
批准号:7205530
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2005
-
负责人:LARRY C BORISH
-
依托单位:
ASPIRIN DESENSITIZATION IN HYPERPLASTIC SINUSITIS
-
批准号:6504432
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:LARRY C BORISH
-
依托单位:
RECOMBINANT HUMAN INTERLEUKIN-4 RECEPTOR IN ASTHMA
-
批准号:6374540
-
项目类别:
-
资助金额:$25.89万
-
财政年份:2000
-
负责人:LARRY C BORISH
-
依托单位:
ASPIRIN DESENSITIZATION IN HYPERPLASTIC SINUSITIS
-
批准号:6566284
-
项目类别:
-
资助金额:$19.07万
-
财政年份:2000
-
负责人:LARRY C BORISH
-
依托单位:
RECOMBINANT HUMAN INTERLEUKIN-4 RECEPTOR IN ASTHMA
-
批准号:6741837
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:LARRY C BORISH
-
依托单位:
海外基金